Curis - CRIS Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings or view top-rated stocks.

3 equities research analysts have issued twelve-month price targets for Curis' shares. Their CRIS share price forecasts range from $4.00 to $15.00. On average, they anticipate the company's share price to reach $9.67 in the next year. This suggests a possible upside of 838.5% from the stock's current price.
View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts.

Curis' stock was trading at $4.76 at the beginning of 2022. Since then, CRIS shares have decreased by 78.4% and is now trading at $1.03.
View the best growth stocks for 2022 here.

Curis is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CRIS earnings forecast.

Curis, Inc. (NASDAQ:CRIS) announced its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.17). Curis had a negative trailing twelve-month return on equity of 68.41% and a negative net margin of 533.89%. During the same period last year, the firm earned ($0.12) earnings per share.

Curis's stock reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Curis' stock is owned by a number of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.56%), Focused Wealth Management Inc (0.45%), Connor Clark & Lunn Investment Management Ltd. (0.04%) and Los Angeles Capital Management LLC (0.03%).
View institutional ownership trends.

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRIS stock can currently be purchased for approximately $1.03.

Curis (NASDAQ:CRIS) has a market capitalization of $94.39 million and generates $10.65 million in revenue each year. The biotechnology company earns $-45,440,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

Curis employs 60 workers across the globe.

Curis was founded in 2000.

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501.